Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robert J. Reaume"'
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Every year pharmaceutical companies use significant resources to mitigate aggregation of pharmaceutical drug products. Specifically, peptides and proteins that have been denatured or degraded can lead to adverse patient reactions such as und
Externí odkaz:
https://doaj.org/article/a6c447a3d1d644eabf20065780207db1
Autor:
Monique J. Farrell, Robert J. Reaume, Erin A. Jenrette, Jasmine Flowers, Kevin C. Santiago, Kyo D. Song, Aswini K. Pradhan
Publikováno v:
Nanomaterials, Vol 9, Iss 10, p 1417 (2019)
The presence of denatured proteins within a therapeutic drug product can create a series of serious adverse effects, such as mild irritation, immunogenicity, anaphylaxis, or instant death to a patient. The detection of protein degradation is complica
Externí odkaz:
https://doaj.org/article/3e95085ecb164207833969ddfa602c8d
Autor:
Aswini K. Pradhan, Monique Farrell, Erin Jenrette, Kevin C. Santiago, Jasmine Flowers, Kyo D. Song, Robert J. Reaume
Publikováno v:
Nanomaterials
Nanomaterials, Vol 9, Iss 10, p 1417 (2019)
Volume 9
Issue 10
Nanomaterials, Vol 9, Iss 10, p 1417 (2019)
Volume 9
Issue 10
The presence of denatured proteins within a therapeutic drug product can create a series of serious adverse effects, such as mild irritation, immunogenicity, anaphylaxis, or instant death to a patient. The detection of protein degradation is complica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa58c9e56b98534013ddda483b5dc7ac
https://pubmed.ncbi.nlm.nih.gov/31590297
https://pubmed.ncbi.nlm.nih.gov/31590297
Publikováno v:
Journal of The Electrochemical Society. 164:B3008-B3012
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfd94cfcac6ff22de8979e77a3376b68
https://doi.org/10.1149/2.0041705jes
https://doi.org/10.1149/2.0041705jes
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Scientific Reports
Scientific Reports
Every year pharmaceutical companies use significant resources to mitigate aggregation of pharmaceutical drug products. Specifically, peptides and proteins that have been denatured or degraded can lead to adverse patient reactions such as undesired im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1a8e1944b5023786d6d454f8626ee7a
https://doi.org/10.1038/s41598-017-02899-3
https://doi.org/10.1038/s41598-017-02899-3